new directions for the treatment of adrenal insufficiency.
Clicks: 340
ID: 146081
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
340 views
32 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #37 of 262 articles by views in aip advances
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 262 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Adrenal disease, whether primary, caused by defects in the hypothalamic-pituitary-adrenal (HPA) axis, or secondary, caused by defects outside the HPA axis, usually results in adrenal insufficiency, which requires lifelong daily replacement of corticosteroids. However this kind of therapy is far from ideal as physiological demand for steroids varies considerably throughout the day and increases during periods of stress. The development of alternative curative strategies is therefore needed. In this review we describe the latest technologies aimed at either isolating or generating de novo cells that could be used for novel, regenerative medicine application in the adrenocortical field.
| Reference Key |
eruiz-babot2015frontiersnew
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Gerard eRuiz-Babot;Irene eHadjidemetriou;Peter James King;Leonardo eGuasti |
| Journal | aip advances |
| Year | 2015 |
| DOI |
10.3389/fendo.2015.00070
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.